A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

NCT02622334 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma

Interventions

DRUG: Latanoprost
DRUG: Placebo
DRUG: RO5093151

Sponsor

Hoffmann-La Roche